டென்மார்க் நோவோ ஹோல்டிங்ஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from டென்மார்க் நோவோ ஹோல்டிங்ஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In டென்மார்க் நோவோ ஹோல்டிங்ஸ் Today - Breaking & Trending Today

Redirecting to Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

December 10, 2020 healthcare
Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
Boehringer Ingelheim today announced the signing of a binding agreement for acquiring all shares of NBE-Therapeutics, a private, clinical-stage Swiss biotechnology company focused on antibody-drug conjugates and advancing targeted cancer therapies derived from its immune stimulatory iADC™ platform. NBE-Therapeutics’ lead compound NBE-002 is currently in phase I clinical studies for triple negative breast cancer and other solid tumors. Importantly, Boehringer Ingelheim gains access to an innovative and unique platform that it will use to build a leading ADC portfolio and develop potential combinations with other assets from its cancer immunology portfolio. ....

Bertrand Damour , Michel Pairet , Denmark Novo Holdings , Boehringer Ingelheim , Boehringer Ingelheim Venture Fund , Managing Directors , Chief Executive Officer , டென்மார்க் நோவோ ஹோல்டிங்ஸ் , போஹெரிங்கர் இஂகல்‌ஹைம் , போஹெரிங்கர் இஂகல்‌ஹைம் துணிகர நிதி , நிர்வகித்தல் இயக்குநர்கள் , தலைமை நிர்வாகி அதிகாரி ,

Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

Boehringer Ingelheim
Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
Friday, December 11, 2020 12:20PM IST (6:50AM GMT)

Ingelheim, Germany & Basel, Switzerland:

Acquisition will add another key dimension to Boehringer Ingelheim’s focus on patients with difficult-to-treat solid tumors
NBE-Therapeutics’pipeline is based on its innovative next generation antibody-drug conjugate (ADC) technology platform
NBE-Therapeutics’will remain at its campus in Basel, Switzerland and operate as a new site within Boehringer Ingelheim’s R&D network

Boehringer Ingelheim today announced the signing of a binding agreement for acquiring all shares of NBE-Therapeutics, a private, clinical-stage Swiss biotechnology company focused on antibody-drug conjugates and advancing t ....

Bertrand Damour , Boehringer Ingelheim , Linda Ruckel , Manel Mateus , Mary Clark , Michel Pairet , Reinhard Malin , Elakiya Rangarajah , Denmark Novo Holdings , Strategic Communications , Boehringer Ingelheim Corporate Center Gmb , Boehringer Ingelheim Venture Fund , Head Of Communications Innovation Unit , Managing Directors , Chief Executive Officer , Media Contact , Communications Innovation Unit , Ingelheim Corporate Center Gmbh , Corporate Reputation , போஹெரிங்கர் இஂகல்‌ஹைம் , லிண்டா றூக்கேள் , மேனல் மத்ேஉச் , மேரி கிளார்க் , ரீன்ஹார்ட் மாலின் , டென்மார்க் நோவோ ஹோல்டிங்ஸ் , மூலோபாய தகவல்தொடர்புகள் ,